The laboratory analysis revealed that, of the 33 samples from the tumor biopsies, 9 (27.3%) had mutations in the KRAS gene and 5 (15.1%) in the NRAS gene, in the genetic positions studied. This evidence concerns the gene KRAS and neoplasm.